Trying to separate three different claims about oxiracetam: that it is the right molecule, that it is the right dose, and that it does something useful.
The comparison group matters more than the compound when the outcome is something as fuzzy as focus.
My rule now: if a claim cannot survive being written down with the numbers attached, it is marketing.
Vivid dreams are reported widely and are not in the label because there is not really a label.
Anyone got a paper worth reading on this rather than a write-up of a paper?
Where does the human data stop and the extrapolation begin? That is the whole thread.
Narrow conclusion, briefly right. Broad conclusion, interestingly wrong. I know which I keep choosing.
This board overrates bloodwork. A number moving is not the outcome you wanted.
This is the kind of post the forum exists for.
Underdosing and tolerance are indistinguishable from the inside, and everyone picks the flattering explanation. Three years in on oxiracetam and it lines up.
Baseline first.
Read methods.
Sterility is the part people wave through and it is the part that actually bites.
Baseline first.
Read methods.
An inconclusive account is useful if it stops the next person mistaking a story for a controlled comparison.
What is the first thing you would read if you were starting from zero?
Nobody has ever been talked out of a stack by a stranger on the internet.
Stupid question: how do you know whether what is in the vial matches the label at all?